Institutional shares held 233 Million
1.18M calls
1.17M puts
Total value of holdings $520M
$2.62M calls
$2.61M puts
Market Cap $352M
157,800,992 Shares Out.
Institutional ownership 147.8%
# of Institutions 293


Latest Institutional Activity in IOVA

Top Purchases

Q2 2025
Millennium Management LLC Shares Held: 9.33M ($20.8M)
Q2 2025
Mhr Fund Management LLC Shares Held: 29M ($64.6M)
Q2 2025
Two Sigma Investments, LP Shares Held: 4.63M ($10.3M)
Q2 2025
Invenomic Capital Management LP Shares Held: 8.29M ($18.5M)
Q2 2025
Long Focus Capital Management, LLC Shares Held: 11.8M ($26.4M)

Top Sells

Q2 2025
Ubs Asset Management Americas Inc Shares Held: 657K ($1.47M)
Q2 2025
Macquarie Group LTD Shares Held: 0 ($0)
Q2 2025
Soleus Capital Management, L.P. Shares Held: 3.26M ($7.27M)
Q2 2025
Vanguard Group Inc Shares Held: 25.1M ($55.9M)
Q2 2025
T. Rowe Price Investment Management, Inc. Shares Held: 182K ($407K)

About IOVA

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.


Insider Transactions at IOVA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
892K Shares
From 9 Insiders
Exercise of conversion of derivative security 831K shares
Open market or private purchase 60.6K shares
Sell / Disposition
409K Shares
From 6 Insiders
Open market or private sale 50K shares
Payment of exercise price or tax liability 359K shares

Track Institutional and Insider Activities on IOVA

Follow IOVANCE BIOTHERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IOVA shares.

Notify only if

Insider Trading

Get notified when an Iovance Biotherapeutics, Inc. insider buys or sells IOVA shares.

Notify only if

News

Receive news related to IOVANCE BIOTHERAPEUTICS, INC.

Track Activities on IOVA